Legal & General Group Plc Acquires New Position in Supernus Pharmaceuticals, Inc. $SUPN

Legal & General Group Plc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 135,434 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,299,000.

A number of other institutional investors and hedge funds have also bought and sold shares of SUPN. Rockefeller Capital Management L.P. raised its stake in shares of Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares in the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $51,000. Hantz Financial Services Inc. grew its holdings in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals in the 2nd quarter worth $55,000. Finally, Osaic Holdings Inc. lifted its stake in Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after purchasing an additional 1,328 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. Cantor Fitzgerald increased their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $62.83.

Supernus Pharmaceuticals Trading Up 0.7%

Supernus Pharmaceuticals stock opened at $44.03 on Thursday. The firm has a market cap of $2.56 billion, a P/E ratio of -22.93, a P/E/G ratio of 0.81 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 1-year low of $42.45 and a 1-year high of $59.68. The firm has a 50-day moving average of $46.77 and a 200-day moving average of $48.49.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). The business had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. Supernus Pharmaceuticals’s quarterly revenue was up 32.4% on a year-over-year basis. During the same period last year, the firm posted $0.40 earnings per share. Research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.